Ocugen Inc. reported a net loss of $0.06 per share for the fourth quarter of 2025, a figure that matched analyst expectations. Quarterly revenue was $193,000, a sharp miss against the consensus estimate of $1.5 million and a negative figure reported by some sources, reflecting a shortfall in collaborative‑arrangement revenue. The loss widened the full‑year 2025 net loss to $0.23 per share, up from $0.20 in 2024 and $0.26 in 2023.
The quarter’s revenue decline is part of a broader trend: Q4 2024 revenue was $0.76 million and Q4 2023 revenue was $1.41 million, while the Q4 2025 loss per share of $0.06 is only slightly higher than the $0.05 loss in Q4 2024 and $0.04 in Q4 2023. R&D expenses rose to $10.7 million from $8.3 million in Q4 2024, reflecting intensified investment in gene‑therapy programs, while general and administrative costs fell modestly to $6.1 million from $6.3 million, indicating some cost discipline amid heavy research outlays.
Ocugen raised $22.5 million in gross proceeds from a registered direct offering, the largest capital raise in its history. The infusion extends the company’s cash runway to the fourth quarter of 2026, with cash and cash equivalents standing at $18.9 million at year‑end. Management noted that the proceeds could push the runway into the second quarter of 2027 if warrants are exercised, providing a buffer for continued clinical development and potential regulatory milestones.
In a statement, Dr. Shankar Musunuri, Chairman, CEO and Co‑founder, said the company had made “considerable development across all our modifier gene‑therapy programs, notable licensing and financing agreements to strengthen our financial position, and meaningful appointments to our leadership team.” He highlighted the company’s progress toward three BLA filings, with OCU400 poised for a Phase 3 data readout in Q1 2027 and OCU410 expected to enter Phase III in 2026.
Investors reacted negatively to the results, citing the revenue miss and the company’s high cash burn. The market’s concerns were amplified by the dilution risk from the $22.5 million offering and the need for additional capital to sustain the clinical pipeline.
The content on EveryTicker is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.